Advances in understanding the pharmacological properties of antisense oligonucleotides.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Advances in Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1054-3589(08)60136-2PMID 9217922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

  1997cited by this paper
• Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).

  1997cited by this paper
• Evaluation of the Toxicity of ISIS 2302, a Phosphorothioate Oligonucleotide, in a 4-Week Study in CD-1 Mice

  1997cited by this paper
• Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

  1997cited by this paper
• Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.

  1997cited by this paper
• Toxicological properties of several novel oligonucleotide analogs in mice.

  1997cited by this paper
• Effect of antisense oligonucleotides on cytokine release from human keratinocytes in an in vitro model of skin.

  1996cited by this paper
• Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.

  1996cited by this paper
• Antisense inhibition of parathyroid hormone-related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat.

  1996cited by this paper
• Nuclease Resistance and Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras*

  1996cited by this paper
• Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

  1996cited by this paper
• Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

  1996cited by this paper
• Inhibition of Growth of Human Tumor Cell Lines in Nude Mice by an Antisense Oligonucleotide Inhibitor of Protein Kinase C-α Expression

  1996cited by this paper
• In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.

  1995cited by this paper
• Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides modulate CYP2B1 expression in vivo.

  1995cited by this paper
• Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV‐infected subjects

  1995cited by this paper
• A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin AT1 receptor.

  1995cited by this paper
• Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

  1995cited by this paper
• Antisense oligonucleotide inhibition of tryptophan hydroxylase activity in mouse brain.

  1995cited by this paper
• Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.

  1995cited by this paper
• Detection of Ribonuclease H-Generated mRNA Fragments in Human Leukemia Cells Following Reversible Membrane Permeabilization in the Presence of Antisense Oligodeoxynucleotides

  1995cited by this paper
• D2 dopamine receptor antisense oligodeoxynucleotide inhibits the synthesis of a functional pool of D2 dopamine receptors.

  1995cited by this paper
• Uptake, Intracellular Distribution, and Stability of Oligodeoxynucleotide Phosphorothioate by Schistosoma mansoni

  1995cited by this paper
• Stability and Pharmacokinetic Characteristics of Oligonucleotides Modified at Terminal Linkages in Mice

  1995cited by this paper
• Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy.

  1995cited by this paper
• Characterization of Binding Sites, Extent of Binding, and Drug Interactions of Oligonucleotides with Albumin

  1995cited by this paper
• Intracerebroventricular administration of angiotensin type 1 (AT1) receptor antisense oligonucleotides attenuate thirst in the rat.

  1995cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper
• Kinetic characteristics of Escherichia coli RNase H1: cleavage of various antisense oligonucleotide-RNA duplexes.

  1995cited by this paper
• Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

  1995cited by this paper
• Oligonucleotide duplex stability controlled by the 7-substituents of 7-deazaguanine bases

  1995cited by this paper
• Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects.

  1995cited by this paper
• Antisense oligodeoxynucleotide to a delta-opioid receptor blocks the antinociception induced by cold water swimming.

  1995cited by this paper
• Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides.

  1995cited by this paper
• In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.

  1995cited by this paper
• Biodistribution and metabolism of internally 3H-labeled oligonucleotides. II. 3',5'-blocked oligonucleotides.

  1995cited by this paper
• Syntheses and properties of novel thiono triester modified antisense oligodeoxynucleotide phosphorothioates

  1995cited by this paper
• PYRANOSYL-RNA ('P-RNA') : BASE-PAIRING SELECTIVITY AND POTENTIAL TO REPLICATE

  1995cited by this paper
• Opioid peptide receptor studies. 4. Antisense oligodeoxynucleotide to the delta opioid receptor delineates opioid receptor subtypes.

  1995cited by this paper
• Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren Oligonucleotide

  1995cited by this paper
• Tricyclic 2'-Deoxycytidine Analogs: Syntheses and Incorporation into Oligodeoxynucleotides Which Have Enhanced Binding to Complementary RNA

  1995cited by this paper
• A New Access to 2′‐O‐Alkylated Ribonucleosides and Properties of 2′‐O‐ Alkylated Oligoribonucleotides.

  1995cited by this paper
• Therapeutic modulation of cytokines.

  1995cited by this paper
• The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism.

  1995cited by this paper
• Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats.

  1995cited by this paper
• A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth

  1995cited by this paper
• The effect of c-fos antisense in the formalin-paw test

  1994cited by this paper
• Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats.

  1994cited by this paper
• Infusion into the brain of an antisense oligonucleotide to the immediate-early gene c-fos suppresses production of fos and produces a behavioral effect.

  1994cited by this paper
• Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.

  1994cited by this paper
• In vivo treatment with antisense oligodeoxynucleotide to κ-opioid receptors inhibited κ-agonist-induced analgesia in rats

  1994cited by this paper
• Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model.

  1994cited by this paper
• Rapid effect on suckling of an oxytocin antisense oligonucleotide administered into rat supraoptic nucleus.

  1994cited by this paper
• Inhibition of rat sexual behavior by antisense oligonucleotides to the progesterone receptor.

  1994cited by this paper
• Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery.

  1994cited by this paper
• Oligodeoxynucleotide antisense to the D1 dopamine receptor mRNA inhibits D1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine.

  1994cited by this paper
• Ventral tegmental area (VTA) injections of tyrosine hydroxylase phosphorothioate antisense oligonucleotide suppress operant behavior in rats.

  1994cited by this paper
• Carbohydrate Modifications in Antisense Research

  1994cited by this paper
• Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion.

  1994cited by this paper
• Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery.

  1994cited by this paper
• Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.

  1994cited by this paper
• Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.

  1994cited by this paper
• Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.

  1994cited by this paper
• Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus.

  1994cited by this paper
• Efficient sequence-specific cleavage of RNA using novel europium complexes conjugated to oligonucleotides.

  1994cited by this paper
• c-fos antisense in rostral ventral medulla reduces arterial blood pressure.

  1994cited by this paper
• 5-Heteroaryl-2'-deoxyuridine Analogs. Synthesis and Incorporation into High-Affinity Oligonucleotides

  1994cited by this paper
• Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids.

  1994cited by this paper
• Cellular Internalization of Oligodeoxynucleotides

  1994cited by this paper
• Learning of the conditioned eye-blink response is impaired by an antisense insulin-like growth factor I oligonucleotide.

  1994cited by this paper
• In vivo administration of an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the expression of D2 dopamine receptors in mouse striatum.

  1994cited by this paper
• Inhibition of c‐Fos Protein Expression in Rat Spinal Cord by Antisense Oligodeoxynucleotide Superfusion

  1994cited by this paper
• Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey

  1994cited by this paper
• Intracerebral administration of antisense oligodeoxynucleotides to GAD65 and GAD67 mRNAs modulate reproductive behavior in the female rat.

  1994cited by this paper
• Biologic and therapeutic significance of MYB expression in human melanoma.

  1994cited by this paper
• 4′-Thio-RNA: A Novel Class of Sugar-Modified β-RNA

  1994cited by this paper
• Sequence‐specific impairment of learning by c-jun antisense oligonucleotides

  1994cited by this paper
• A convergent synthesis of 2′-o-methyl uridine

  1994cited by this paper
• Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities.

  1994cited by this paper
• Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion.

  1994cited by this paper
• Modulation of substance P/neurokinin-1 receptor in human astrocytoma cells by antisense oligodeoxynucleotides.

  1994cited by this paper
• Treatment with antisense oligodeoxynucleotide to the opioid δ receptor selectively inhibits δ2-agonist antinociception

  1994cited by this paper
• Amphetamine regulates gene expression in rat striatum via transcription factor CREB

  1994cited by this paper
• Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genes

  1994cited by this paper
• Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines.

  1993cited by this paper
• Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

  1993cited by this paper
• Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

  1993cited by this paper
• Antisense oligonucleotide blocks progesterone-induced lordosis behavior in ovariectomized rats.

  1993cited by this paper
• Tritium labeling of antisense oligonucleotides by exchange with tritiated water.

  1993cited by this paper
• Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.

  1993cited by this paper
• Antisense oligonucleotides made of 2'‐O‐alkylRNA: their properties and applications in RNA biochemistry

  1993cited by this paper
• In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts

  1993cited by this paper
• Antisense inhibition of AT1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin.

  1993cited by this paper
• Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines.

  1993cited by this paper
• C-fos antisense in the nucleus accumbens blocks the locomotor stimulant action of cocaine.

  1993cited by this paper
• Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in Mice

  1993cited by this paper
• Progress toward oligonucleotide therapeutics: pharmacodynamic properties

  1993cited by this paper
• Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression.

  1993cited by this paper
• Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets.

  1993cited by this paper
• In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.

  1993cited by this paper

• Research on Preparation and in Vitro Evaluation of the Dendrimer-PNA Conjugate for Amplification Pretargeting.

  2021cites this paper
• In vivo and in vitro studies of antisense oligonucleotides – a review

  2020cites this paper
• A Revisit to the Pretargeting Concept—A Target Conversion

  2018cites this paper
• THE ROLE OF PXR AND IKKβ SIGNALING IN CARDIOMETABOLIC DISEASE

  2016cites this paper
• Targeting IκB kinase β in Adipocyte Lineage Cells for Treatment of Obesity and Metabolic Dysfunctions

  2016cites this paper
• The TMAO-Generating En zyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance Graphical

  2015cites this paper
• The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance.

  2015cites this paper
• α/β Hydrolase Domain-containing 6 (ABHD6) Degrades the Late Endosomal/Lysosomal Lipid Bis(monoacylglycero)phosphate

  2015cites this paper
• Review Article Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy

  2014cites this paper
• Receptor-targeted drug delivery: current perspective and challenges.

  2014cites this paper
• Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.

  2014cites this paper
• The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome.

  2013cites this paper
• Advances in targeted therapeutic agents

  2010cites this paper
• Radiolabelled Oligonucleotides for Evaluation of in vivo Hybridisation Utilising PET Methodology

  2007cites this paper
• Pharmacokinetics and Biodistribution of Novel Aptamer Compositions

  2004cites this paper
• Identification of Hybridization Accessible Sequence in Messenger RNA

  2004cites this paper
• Antisense Tcf inhibits the neoplastic growth of liver cancer cells

  2004cites this paper
• Microencapsulation of Tumor Necrosis Factor Oligomers: A New Approach to Proinflammatory Cytokine Inhibition

  2003cites this paper
• Antisense oligonucleotides: design, construction, and applications to cardiac allograft transfer.

  2003cites this paper
• Ten years of antisense inhibition of brain G-protein-coupled receptor function.

  2003cites this paper
• Gene, Oligonucleotide, and Ribozyme Therapy in the Eye

  2003cites this paper
• Functional study of rat 5‐HT2A receptors using antisense oligonucleotides

  2003influential citation
• In Vivo Pro-Apoptotic and Antitumor Efficacy of a c-Raf Antisense Phosphorothioate Oligonucleotide: Relationship to Tumor Size

  2002cites this paper
• Fomivirsen

  2002cites this paper
• Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.

  2002cites this paper
• Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS.

  2002cites this paper
• 2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN (TCDD)-INDUCED DOWN-REGULATION OF GLUCOSE TRANSPORTING ACTIVITIES IN MOUSE 3T3-L1 PREADIPOCYTE

  2002cites this paper
• Cardiac Cell and Gene Transfer

  2002cites this paper
• A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma

  2001cites this paper
• Interleukin-12 Gene Therapy Vaccines: Directing the Immune System against Minimal Residual Leukemia

  2001cites this paper
• Oligodeoxynucleotides with extended zwitter-ionic internucleotide linkage

  2001cites this paper
• Suppression of β-Catenin Inhibits the Neoplastic Growth of APC-Mutant Colon Cancer Cells

  2001cites this paper
• Gene Therapy for the Management of Pain: Part I: Methods and Strategies

  2001cites this paper
• Liquid-phase synthesis of a cyclic hexameric peptide nucleic acid

  2001cites this paper
• Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.

  2000cites this paper
• Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor‐mediated process

  2000cites this paper
• Linking gustatory neurobiology to behavior in vertebrates.

  2000cites this paper
• Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides.

  2000cites this paper
• Oligonucleotide-based drugs in the control of cytokine synthesis

  2000cites this paper
• Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.

  2000cites this paper
• Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.

  2000cites this paper
• Knock down of spinal NMDA receptors reduces NMDA and formalin evoked behaviors in rat

  2000cites this paper
• Down-Regulation of HER 2 / neu Expression Induces Apoptosis in Human Cancer Cells That Overexpress HER 2 / neu 1

  2000cites this paper
• In vitro transport and delivery of antisense oligonucleotides.

  2000cites this paper
• Novel cationic amphiphiles as delivery agents for antisense oligonucleotides.

  1999cites this paper
• NMR structure of an antisense DNA.RNA hybrid duplex containing a 3'-CH(2)N(CH(3))-O-5' or an MMI backbone linker.

  1999cites this paper
• Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides

  1999cites this paper
• Antisense and nuclear medicine.

  1999cites this paper
• Antisense RNA gene therapy for studying and modulating biological processes

  1999cites this paper
• Antisense oligonucleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum.

  1999cites this paper
• Gene therapy and vascular disease.

  1999cites this paper
• Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

  1999cites this paper
• Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents.

  1999cites this paper
• Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression*

  1999cites this paper
• Gene therapy for leukemia and lymphoma.

  1998cites this paper
• Antisense Research and Application

  1998cites this paper
• Introduction: antisense oligonucleotides: strategies and successes.

  1998cites this paper
• Real time detection of DNA.RNA hybridization in living cells.

  1998cites this paper
• Clinical Antiviral Activities

  1998cites this paper
• The antisense strategy applied to the study of dopamine D3 receptor functions in rat forebrain.

  1998cites this paper
• Antisense-Oligonucleotide – ein universelles Therapieprinzip

  1998cites this paper
• Antisense oligonucleotides as emerging drugs

  1998cites this paper
• The Use of Antisense Technologies to Understand Neural Functioning: Fact or Fiction?

  1998cites this paper
• Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.

  1998cites this paper
• Nucleic acid therapeutics: state of the art and future prospects.

  1998cites this paper